Across TCGA pan-cancer cohorts, KLRG2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated KLRG2 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher KLRG2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated KLRG2 expression acts as an unfavorable survival marker.

SKCM, STAD, and ACC are the cancer types where KLRG2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	All	0.188	0.741	<.001	21	view →
STAD	OS	Median	II,III,IV	0.183	0.660	.009	12	view →
ACC	DFS	Median	II,III,IV	0.242	0.724	.034	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: KLRG2 tumor-vs-normal RNA expression · all KLRG2 data types